Selective estrogen receptor modulator raloxifene-associated aggravation of nonalcoholic steatohepatitis

Internal Medicine

Volumn 46, Issue 9, 2007, Pages 579-581

  Takamura, Toshinari ^a   Shimizu, Akiko ^a   Komura, Takuya ^a   Ando, Hitoshi ^a   Zen, Yoh ^b   Minato, Hiroshi ^b   Matsushita, Eiki ^c   Kaneko, Shuichi ^a  

^a KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

^b KANAZAWA UNIVERSITY HOSPITAL   (Japan)

^c Kahoku Central Hospital   (Japan)

Author keywords

Estrogen; Estrogen receptor modulators; Fatty liver; Nonalcoholic steatohepatitis; Osteoporosis; Postmenopausal

Indexed keywords

ANTIRHEUMATIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; RALOXIFENE; VITAMIN D; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

ADULT; ARTHRALGIA; ARTICLE; BLOOD CHEMISTRY; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DRUG WITHDRAWAL; FAMILY HISTORY; FATTY LIVER; FEMALE; GLUCOSE INTOLERANCE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INSULIN RESISTANCE; LIVER BIOPSY; LIVER DYSFUNCTION; NONALCOHOLIC FATTY LIVER; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOPOROSIS; POSTMENOPAUSE; RHEUMATOID ARTHRITIS; SIDE EFFECT; SJOEGREN SYNDROME; WEIGHT GAIN; BLOOD; CHEMICALLY INDUCED DISORDER; ENZYMOLOGY; HOSPITALIZATION; LIVER; LIVER CIRRHOSIS; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; POSTMENOPAUSE OSTEOPOROSIS; RISK FACTOR; TOXIC HEPATITIS;

ALANINE TRANSAMINASE; ASPARTATE AMINOTRANSFERASES; FATTY LIVER; FEMALE; GLUCOSE INTOLERANCE; HEPATITIS, TOXIC; HUMANS; INSULIN RESISTANCE; LIVER; LIVER CIRRHOSIS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; RALOXIFENE; RISK FACTORS; SELECTIVE ESTROGEN RECEPTOR MODULATORS; SEVERITY OF ILLNESS INDEX;

EID: 34249663150     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.46.6374     Document Type: Article

References (5)

1. Loose DS, Stancel GM. Estrogens and progestins. In: Goodman & Gilman's The Pharmacological Basis of Therapeutics. 11 ed. Brunton LL, Lazo JS, Parker KL, Eds. McGraw-Hill, New York, 2006: 1541-1571.
2. Ogawa Y, Murata Y, Nishioka A, Inomata T, Yoshida S. Tamoxifen-induced fatty liver in patients with breast cancer. Lancet 351: 725, 1998.
3. Bruno S, Maisonneuve P, Castellana P, et al. Incidence and risk factors for non-alcoholic steatohepatitis: prospective study of 5408 women enrolled in Italian tamoxifen chemoprevention trial. BMJ 330: 932, 2005.
4. Shimizu I. Impact of oestrogens on the progression of liver disease. Liver Int 23: 63-69, 2003.
5. Vilches AR, Perez V, Suchecki DE. Raloxifene-associated hepatitis. Lancet 352: 1524-1525, 1998.